SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1538980
The efficacy and safety of Tisotumab Vedotin in the treatment of recurrent/metastatic cervical cancer: a systematic review and meta-analysis of single-arm studies
Provisionally accepted
- 1Department of Gynecology and Obstetrics, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan Province, China
- 2Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
- 3Radiology department，XinDu Hospital of Traditional Chinese Medicine，Chengdu，China, Chengdu, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study was conducted to evaluate the efficacy and safety of Tisotumab Vedotin (TV) in the treatment of recurrent/metastatic cervical cancer (r/m CC) through a systematic review and meta-analysis.Methods: The clinical studies on the monotherapy of TV for r/m CC were retrieved comprehensively from some databases, including PubMed, Embase, and Cochrane Library. The inclusion criteria encompassed observational studies and randomized controlled trials. Data analysis was performed using STATA 15.0. Besides, the median overall survival (OS), median progression-free survival (PFS), disease control rate (DCR), objective response rate (ORR), and the incidence of adverse events (AEs) and AEs at Grades 3-5 were calculated.Results: A total of 5 articles (covering 7 studies and 527 patients) were included in this study. The meta-analysis results revealed that the median OS, median PFS, ORR, and DCR were 11.83 months, 4.22 months, 29.9%, and 75.1%, respectively, for patients treated with TV. The incidence of AEs was 99.1%, and AEs at Grades 3-5 were reported in 61.7% of patients.Conclusion: TV demonstrates significant efficacy as a second-line or third-line therapy for r/m CC, making it a promising therapeutic option. Nevertheless, large-scale randomized controlled trials are needed to validate these findings and optimize clinical application strategies.
Keywords: Tisotumab vedotin, recurrent, Metastatic, cervical cancer, Antibodydrug conjugate, prognosis
Received: 03 Dec 2024; Accepted: 23 Apr 2025.
Copyright: © 2025 Zeng, Li, Xiao, Yang, Changsheng, Chen, Zhao and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hu Zhao, Department of Gynecology and Obstetrics, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan Province, China
Xue Xiao, Department of Gynecology and Obstetrics, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.